

Submission Instructions to Journal Materials Today: Proceedings

1. Submission to [Materials Today: Proceedings](#):

- Step 1:** Please download the Materials Today: Proceedings Template by clicking "[Materials Today: Proceedings Template](#)".
- Step 2:** Ensure that you have read Author guidelines carefully before submitting a paper to ICE3MT 2022. Please refer to the link for Author guidelines. <https://www.elsevier.com/journals/materials-today-proceedings/2214-7853/guide-for-authors>
- Step 3:** For initial screening and review, authors should send their full-length article (in pdf format) to ICARES-2022 through the **EasyChair** **link** <https://easychair.org/conferences/?conf=icares2022>
- Step 4:** Following an initial screening and assessment for scope, plagiarism, and originality, the conference committee will contact the corresponding authors of submitted papers to coordinate the next stage (i.e., conference registration and presentation).
- Step 5:** All the manuscripts cleared in first round and registered and presented in the ICARES 2022 are now invited to submit their papers to Materials Today Proceedings via the Elsevier Editorial Manager at <https://www.editorialmanager.com/matpr/default1.aspx> for the second

level review and publication. **This process begins from 03rdDecember 2022.**

6. **Step 6:** To submit a paper through Elsevier Editorial Manager (post conference), corresponding authors must create an author account in the Elsevier Editorial System by clicking on the link <https://www.editorialmanager.com/matpr/default1.aspx> (ignore this step if you already have an account with Materials Today: Proceedings).
7. **Step 7:** Login as **Author** using the above link.
8. **Step 8:** After author login, under **New Submissions**, click the icon **‘Submit New Manuscript’**. Select Article Type as **SI: ICARES 2022**. Then click **Proceed** button.
9. **Step 9:** Then follow all subsequent instructions to complete the submission of your paper.
10. **Step 10:** Now, all submitted papers will undergo a double-blind review process.